Last reviewed · How we verify
ARALAST Alpha1-Proteinase Inhibitor — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
ARALAST Alpha1-Proteinase Inhibitor (ARALAST Alpha1-Proteinase Inhibitor) — Baxalta now part of Shire.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ARALAST Alpha1-Proteinase Inhibitor TARGET | ARALAST Alpha1-Proteinase Inhibitor | Baxalta now part of Shire | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ARALAST Alpha1-Proteinase Inhibitor CI watch — RSS
- ARALAST Alpha1-Proteinase Inhibitor CI watch — Atom
- ARALAST Alpha1-Proteinase Inhibitor CI watch — JSON
- ARALAST Alpha1-Proteinase Inhibitor alone — RSS
Cite this brief
Drug Landscape (2026). ARALAST Alpha1-Proteinase Inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/aralast-alpha1-proteinase-inhibitor. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab